Although the remote consultation for the public has experienced explosive growth in the United States, the industry growth ceiling has emerged. Although the control fee is the main driving force for remote consultation, the employer as the main payer is increasingly convinced that remote consultation is only a means to improve accessibility rather than a means of controlling fees. Therefore, employers purchase separate consultation services for remote consultation services. The will is weakening. This makes remote consultations only become value-added services for insurance companies. Moreover, there is not much competitive advantage for remote consultations based on minor illnesses. Market competition will become increasingly fierce. Once insurance companies operate such services themselves, The development of third parties has been severely squeezed. In order to stabilize the source of customers and to break through the ceiling of the industry, the remote consultation company began to focus on the field of chronic disease management, with the intention of expanding the market size and achieving steady growth by placing remote consultation services to the slow patient population. According to a survey conducted by the US RAND Corporation a year ago, the remote consultation with Teladoc was mainly for users under the age of 51 without chronic diseases. According to recent sharing by UnitedHealth, the typical users of remote consultations are women around 31 years old, and more than 50% of them are looking for respiratory diseases. This shows that the remote consultation mainly solves the minor illness, and it is a one-time treatment, and the user is not sticky. As the "telemedicine employer market: insurance products vassal" of the analysis, remote interrogation is divided into in two by membership fees and the actual number of occurrences, mainly due Teladoc membership fee model, that regardless of whether the interrogation occurred, Employers must pay by head, which makes their future growth face a big bottleneck. Doctor on Demand and American Well charge the actual number of times, and more insured companies purchase it into their value-added services as a means of improving user accessibility, rather than control fees. Therefore, no matter which mode, although the current growth is still relatively fast, reaching a level that nearly doubles every year, but with the reduction of users who are willing to purchase, the lack of future growth is inevitable. Tapioca Fiber,Tapioca Dextrin,Tapioca Dextrin Fiber,Indigestible Tapioca Dextrin,Low Sugar Tapioca Fiber Shandong Bailong Chuangyuan Bio-tech Co.,Ltd. Qingdao Branch , https://www.qdblcycn.com